Posted: April 22, 2010

Compugen Announces New Drug Discovery Platform to Predict Peptides that Block Protein - Protein Interactions

(Nanowerk News) Compugen Ltd. announced today the development of its Protein-Protein Interaction Blockers (PPI Blockers) Discovery Platform, designed for the prediction of peptides to block disease associated protein-protein interactions. In a pilot validation run, predicted peptides showed positive results for drug targets in two cancer related pathways of interest to the industry.
The PPI Blockers Discovery Platform consists of two main components. The first component creates a predicted protein-protein interaction map for the protein target of interest in a selected biological pathway. This map is based on both the target’s known protein partners and additional proteins predicted by Compugen as potential partners through the analysis of human and non-human proteomes and interaction data.
The second component, applied to all relevant key proteins of the pathway, is based on identifying computationally the predicted protein-protein binding segments through sequence and structural characteristics. The identification of these segments allows the design and selection of peptides that could serve as drugs by blocking all or a portion of the interacting site. These peptide blockers may either serve as therapeutic peptides or be used as epitopes for the development of therapeutic antibodies. A key advantage of the platform is that it is designed to predict peptides that block a wide range of target proteins and can do so without any knowledge of the three-dimensional structure of the target.
Dr. Zurit Levine, Compugen’s VP R&D, stated, “Both the interaction with another protein (‘protein-protein interaction’) and the formation of a specific conformation through the interaction of separate segments of the same protein (‘intra-molecular interaction’) are required for proteins to exert their function. Therefore blocking one or both of these phenomena as an approach for drug therapy is of intense research worldwide. However, relying on conventional large-scale experimental discovery methods such as screening thousands of compounds or peptides per target has resulted in an extremely low discovery rate of molecules with the required inhibitory effects.”
Dr. Levine continued, “With the development of the PPI Blockers Discovery Platform to predict peptide blockers for protein-protein interaction, and the availability of our previously announced DAC Blockers Platform to predict peptides to block intra-protein binding, Compugen now has the capability to design blocking peptides for both of these key biological phenomena. It is anticipated that this approach will be applicable to a wide range of indications, based on the association of potential target proteins or protein-protein interactions to unmet clinical needs. These two discovery platforms, together with Compugen’s ten other discovery platforms, provide unique and powerful capabilities for enhanced product candidate discovery by Compugen and for potential use in additional 'discovery on demand' collaborations.”
About Protein – Protein Interactions
Protein-protein interactions are central to many key biological functions and thus are attractive targets for a host of diseases. Therefore, the therapeutic applications of inhibiting protein-protein interactions are potentially wide-ranging. However, most efforts so far to discover molecules that modulate protein-protein interactions have been largely unsuccessful, and researchers have long considered them to be “undruggable”.
About Compugen
Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugen’s discovery efforts are based on in silico (by computer) prediction and selection utilizing a growing number of field focused proprietary discovery platforms accurately modeling biological processes at the molecular level. Compugen’s growing number of collaborations with major pharmaceutical and diagnostic companies cover both (i) the licensing of product candidates discovered by Compugen during the validation of its discovery platforms and in its internal research, and (ii) “discovery on demand” agreements where existing or new Compugen discovery platforms are utilized to predict and select product candidates as required by a partner. In 2002, Compugen established an affiliate, Evogene Ltd. (, to utilize certain of the Company’s in silico predictive discovery capabilities in agricultural biotechnology.
Source: Compugen (press release)
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: